U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438444) titled 'A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity' on Feb. 23.
Brief Summary: The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus, Type 2
Obesity
Overweight
Intervention:
DRUG: Tirzepatide
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Publi...